Clinical Rheumatology

, Volume 34, Issue 11, pp 1989–1992 | Cite as

Hyperferritinemic syndrome: Still’s disease and catastrophic antiphospholipid syndrome triggered by fulminant Chikungunya infection: a case report of two patients

  • Juan-Felipe Betancur
  • Erika-Paola Navarro
  • Alex Echeverry
  • Pablo A. Moncada
  • Carlos A. Cañas
  • Gabriel J. Tobón
Case Based Review


There are four medical conditions characterized by high levels of ferritin, the macrophage activation syndrome (MAS), adult onset Still’ s disease (AOSD), catastrophic antiphospholipid syndrome (CAPS), and septic shock, that share similar clinical and laboratory features, suggesting a common pathogenic mechanism. This common syndrome entity is termed “the hyperferritinemic syndrome.” Here, we describe two different cases of hyperferritinemic syndrome triggered by Chikungunya fever virus infection: a 21-year-old female with SLE and a 32-year-old male patient who developed AOSD after the coinfection of dengue and Chikungunya viruses.


Adult onset Still’s disease Catastrophic antiphospholipid syndrome Chikungunya virus infection Ferritin Hyperferritinemic syndrome 





  1. 1.
    Knovich MA, Storey JA, Coffman LG, Torti SV, Torti FM (2009) Ferritin for the clinician. Blood Rev 23(3):95–104PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Rosário C, Zandman-Goddard G, Meyron-Holtz EG, D’Cruz DP, Shoenfeld Y (2013) The hyperferritinemic syndrome: macrophage activation syndrome, Still’s disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med 11:185–195PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Rosário C, Shoenfeld Y, Hon F (2014) The hyperferritinemic syndrome. IMAJ 16:10–11Google Scholar
  4. 4.
    Mehta B, Efthimiou P (2012) Ferritin in adult-onset Still’s disease: just a useful innocent bystander? Int J Inflam 2012:254858PubMedCentralGoogle Scholar
  5. 5.
    Agmon-Levin N, Rosário C, Katz B-SP, Zandman-Goddard G, Meroni P, Cervera R et al (2013) Ferritin in the antiphospholipid syndrome and its catastrophic variant (cAPS). Lupus 22(13):1327–1335CrossRefPubMedGoogle Scholar
  6. 6.
    Getts DR, Chastain EM, Terry RL, Miller SD (2013) Virus infection, antiviral immunity, and autoimmunity. Immunol Rev 255(1):197–209PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Wouters JM, van der Veen J, van de Putte LB, de Rooij DJ (1988) Adult onset Still’s disease and viral infections. Ann Rheum Dis 47(9):764–767PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Ortega-Hernandez O-D, Agmon-Levin N, Blank M, Asherson RA, Shoenfeld Y (2009) The physiopathology of the catastrophic antiphospholipid (Asherson’s) syndrome: compelling evidence. J Autoimmun 32(1):1–6CrossRefPubMedGoogle Scholar
  9. 9.
    Campion EW, Weaver SC, Lecuit M (2015) Chikungunya virus and the global spread of a mosquito-borne disease. N Engl J Med 372(13):1231–1239CrossRefGoogle Scholar
  10. 10.
    Calabrese LH (2008) Emerging viral infections and arthritis: the role of the rheumatologist. Nat Clin Pract Rheumatol 4(1):2–3CrossRefPubMedGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2015

Authors and Affiliations

  • Juan-Felipe Betancur
    • 1
  • Erika-Paola Navarro
    • 1
  • Alex Echeverry
    • 2
  • Pablo A. Moncada
    • 3
  • Carlos A. Cañas
    • 2
  • Gabriel J. Tobón
    • 2
    • 4
  1. 1.Department of Internal MedicineCES University, School of Medicine, Medellín-Colombia and Fundación Valle del LiliCaliColombia
  2. 2.Rheumatology Unit. Fundación Valle del LiliIcesi UniversityCaliColombia
  3. 3.Infectious Diseases Unit. Fundación Valle del LiliCaliColombia
  4. 4.Laboratory of Immunology. Fundación Valle del LiliCaliColombia

Personalised recommendations